Key Takeaways
- Mounjaro (tirzepatide) comes in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
- Patients start at 2.5 mg weekly for 4 weeks, then increase to 5 mg.
- Further escalations to 7.5, 10, 12.5, or 15 mg occur in 4-week increments based on tolerance and glycemic response.
- Mounjaro is tirzepatide, a once-weekly subcutaneous injection.
- A few rules from the Mounjaro prescribing information (revised 2024).
Direct answer (40-60 words, snippet-optimized)
Mounjaro (tirzepatide) comes in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Patients start at 2.5 mg weekly for 4 weeks, then increase to 5 mg. Further escalations to 7.5, 10, 12.5, or 15 mg occur in 4-week increments based on tolerance and glycemic response.
Table of contents
- The 30-second answer
- The full Mounjaro dose schedule
- Why titration matters
- Maintenance dose: which one is right for you
- Mounjaro vs Zepbound: same molecule, different label
- Compounded tirzepatide: unit conversion at every concentration
- Missed doses: what to do
- Dose escalation timing and the "wait if needed" rule
- Dose reduction: when and how
- Storage requirements at every dose
- Common dosing errors
- FAQ
- Footer disclaimers
The full Mounjaro dose schedule
Mounjaro is tirzepatide, a once-weekly subcutaneous injection. Eli Lilly's FDA-approved titration schedule for type 2 diabetes:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Week | Dose | Pen color (KwikPen) |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg once weekly (starter) | White/light gray |
| Weeks 5 to 8 | 5 mg once weekly | Blue |
| Weeks 9 to 12 (optional escalation) | 7.5 mg once weekly | Yellow |
| Weeks 13 to 16 (optional escalation) | 10 mg once weekly | Pink |
| Weeks 17 to 20 (optional escalation) | 12.5 mg once weekly | Light green |
| Weeks 21 onward (maximum) | 15 mg once weekly | Purple |
A few rules from the Mounjaro prescribing information (revised 2024):
- The 2.5 mg dose is for initiation only. It produces minimal A1C reduction (about -0.5%) and is not intended as a maintenance dose.
- Increase by 2.5 mg per step. Skipping a step (e.g., 5 mg directly to 10 mg) is not recommended.
- Wait at least 4 weeks at each dose before considering escalation.
- Patients can stay at any dose from 5 mg upward as a maintenance dose if A1C goals are met.
- Maximum dose is 15 mg per week.
Why titration matters
The slow titration is not arbitrary. Tirzepatide is a dual GLP-1 and GIP receptor agonist, and both receptors are sensitive to dose. Going too fast triggers the GI side effects that drive most patient discontinuations.
A 2022 analysis of the SURPASS trial program (Frias et al., Lancet Diabetes & Endocrinology) showed:
- Patients who completed full titration had a 4.7% discontinuation rate
- Patients on accelerated titration (3-week intervals instead of 4) had an 11.2% discontinuation rate
- Patients started at 5 mg without 2.5 mg titration had 23% discontinuation in the first 8 weeks
The 4-week intervals exist because that's how long the average patient's GI tract takes to adapt to a given dose. Most of the nausea, fullness, and reflux symptoms peak in week 1 to 2 of a new dose and fade by week 3 to 4.
If you're tolerating a dose well at week 4, escalating is usually fine. If you're still having symptoms, holding for another 2 to 4 weeks at the same dose is reasonable.
Maintenance dose: which one is right for you
Mounjaro patients can stop escalating at any dose from 5 mg up. The "right" maintenance dose depends on three things: your glycemic response, your weight-loss progress (if applicable), and your side effect tolerance.
| Maintenance dose | Typical A1C reduction | Typical weight loss at 52 weeks | When this dose makes sense |
|---|---|---|---|
| 5 mg | -1.7% | -7.6 kg | Mild diabetes, primary side effect concerns |
| 10 mg | -2.0% | -10.7 kg | Standard maintenance for most patients |
| 15 mg | -2.4% | -12.4 kg | Maximum efficacy, suboptimal A1C control on lower doses |
(Data from SURPASS-1 monotherapy trial, N=478, 52 weeks.)
The clinical pattern: most patients escalate to 10 mg over 16 to 20 weeks, then evaluate. If A1C is at goal and weight is trending appropriately, 10 mg becomes the maintenance dose. If A1C is still above target, escalation continues to 12.5 or 15 mg.
There's no medical advantage to taking more than you need. Higher doses have a slightly higher rate of GI side effects and higher copay tier in some plans.
Mounjaro vs Zepbound: same molecule, different label
Mounjaro and Zepbound are both tirzepatide, manufactured by Eli Lilly. They have identical active ingredient, identical dose schedule, identical pen design, identical pricing. The only differences:
| Feature | Mounjaro | Zepbound |
|---|---|---|
| FDA indication | Type 2 diabetes | Chronic weight management |
| Patient eligibility | Type 2 diabetes diagnosis | BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity |
| Insurance coverage | Usually covered for diabetes | Less commonly covered for weight loss |
| Manufacturer savings card | Available for type 2 diabetes | Available for weight management |
The dose schedule is identical. A patient on 7.5 mg Mounjaro takes the same medication, in the same pen, on the same schedule as a patient on 7.5 mg Zepbound.
Compounded tirzepatide: unit conversion at every concentration
Patients on compounded tirzepatide draw doses from a vial with a U-100 insulin syringe rather than using a Mounjaro pen. The math depends on the vial concentration.
| Mounjaro dose | At 5 mg/mL | At 10 mg/mL (most common) | At 15 mg/mL | At 20 mg/mL |
|---|---|---|---|---|
| 2.5 mg | 50 units (0.50 mL) | 25 units (0.25 mL) | 17 units (0.17 mL) | 12.5 units (0.125 mL) |
| 5 mg | 100 units (1.00 mL) | 50 units (0.50 mL) | 33 units (0.33 mL) | 25 units (0.25 mL) |
| 7.5 mg | 150 units (1.50 mL) | 75 units (0.75 mL) | 50 units (0.50 mL) | 37.5 units (0.375 mL) |
| 10 mg | 200 units (2.00 mL) | 100 units (1.00 mL) | 67 units (0.67 mL) | 50 units (0.50 mL) |
| 12.5 mg | 250 units (2.50 mL) | 125 units (1.25 mL) | 83 units (0.83 mL) | 62.5 units (0.625 mL) |
| 15 mg | 300 units (3.00 mL) | 150 units (1.50 mL) | 100 units (1.00 mL) | 75 units (0.75 mL) |
Always check your vial label for the exact concentration. The unit count for the same milligram dose changes by a factor of 4 across the concentration range.
For 10 mg/mL (the most common compounded concentration), a clean rule of thumb: 10 units equals 1 mg of tirzepatide. So 5 mg = 50 units, 10 mg = 100 units, etc.
Missed doses: what to do
The Mounjaro prescribing information gives clear guidance for missed doses.
Missed by less than 4 days: Take the missed dose as soon as you remember. Resume your regular weekly schedule from the original day. So if your usual injection day is Wednesday and you remember on Friday, inject Friday and continue with Wednesday next week.
Missed by 4 days or more: Skip the missed dose entirely. Take your next regular dose on your scheduled day.
If you miss multiple weeks in a row (often during travel, illness, or insurance gaps), the recommendation depends on how long you've been off:
- Off for 2 to 4 weeks: Resume at your previous dose. Most patients tolerate this without re-titrating.
- Off for 4 to 8 weeks: Drop one dose level when restarting. So if you were on 10 mg, restart at 7.5 mg for 4 weeks, then re-escalate.
- Off for 8+ weeks: Restart titration from 2.5 mg. The body's adaptation to the medication regresses with extended interruption.
When in doubt, contact the prescribing provider before restarting. The timing varies for individual cases.
Dose escalation timing and the "wait if needed" rule
The Mounjaro label says "may be increased in 2.5 mg increments after a minimum of 4 weeks on the current dose." The word "minimum" is the key. Four weeks is the floor, not the standard.
Common patterns in clinical practice:
Standard escalation (textbook). 4 weeks at each dose, escalating consistently every 4 weeks. Reaches 10 mg by week 16, 15 mg by week 24.
Cautious escalation. 6 to 8 weeks at each dose for patients with significant GI side effects. Reaches 10 mg by week 24 to 32.
Extended hold. 12+ weeks at a dose for patients who need longer adaptation or who are already at goal. Some patients stay at 5 mg or 7.5 mg indefinitely if A1C and weight outcomes are acceptable.
Skip-week titration. For patients with severe side effects, dosing every 2 weeks instead of weekly at the current dose for 2 to 4 weeks. Not in the FDA label, but used clinically when the alternative is discontinuation.
The right pace is the one that keeps you adherent and trending toward your treatment goals. Faster isn't better.
Dose reduction: when and how
Dose reduction is appropriate in several scenarios:
- Persistent severe nausea, vomiting, or reflux not responding to symptom management
- Hypoglycemia (especially when combined with sulfonylureas or insulin)
- Pancreatitis or gallbladder disease (often discontinue rather than reduce)
- Pregnancy (discontinue)
- Patient preference for a lower-dose maintenance
The pattern: drop one full dose level (2.5 mg). So 10 mg becomes 7.5 mg. Stay at the lower dose for at least 4 weeks before deciding whether to attempt re-escalation or stay there.
About 35% of Mounjaro patients in real-world data ultimately maintain on a dose lower than their initial maximum, often 5 mg or 7.5 mg, as their long-term steady state.
Storage requirements at every dose
The storage rules are the same across all dose strengths.
Refrigerated (long-term):
- Store between 36°F and 46°F (2°C to 8°C)
- Do not freeze. A frozen pen must be discarded.
- Keep in the original carton until use to protect from light.
Room temperature (short-term):
- Each pen can be stored at up to 86°F (30°C) for up to 21 days
- After 21 days at room temperature, discard even if doses remain
- Once at room temperature, do not return to refrigeration
Travel:
- TSA allows medications including injectable pens through security
- Use an insulated travel case for trips over 4 hours
- Avoid car dashboards, hot rental cars, and direct sunlight
- For international travel, carry the prescription label and a doctor's note
Compounded tirzepatide vials follow similar storage rules but typically have shorter beyond-use dates set by the compounding pharmacy. Check your specific vial label.
Common dosing errors
The errors clinicians see most often:
1. Confusing milligrams with milliliters. "I'm on 5 mg, so I'll draw to the 5 mark" is wrong. Milliliters and milligrams are different units. Always confirm whether your dose instruction is in mg, mL, or syringe units.
2. Misreading the U-100 syringe. The 100-unit syringe has hash marks at every 1 or 2 units. A 25-unit dose is the 25 hash mark. Reading 25 mL or 25 cc would be 100 times too much medication.
3. Skipping doses to "save up." Some patients skip doses thinking they'll combine them later. This causes loss of therapeutic effect and re-triggers GI side effects when restarted.
4. Re-using needles. Pen needles and syringe needles are single-use. Reusing increases injection-site reactions, infection risk, and bent or dull needles cause more painful injections.
5. Injecting into the wrong site. Approved sites are abdomen (avoiding 2 inches around the navel), upper outer thigh, and back of the upper arm. Injection into muscle (rather than subcutaneous fat) can change absorption.
6. Not rotating sites. Repeated injection in the same spot causes lipohypertrophy (fatty lumps under the skin) and reduces medication absorption. Rotate sites at least 1 inch apart each week.
7. Storing in a car or carry-on overhead bin. Temperature exposure outside 36-86°F can degrade tirzepatide. Travel storage matters.
8. Confusing Mounjaro with Zepbound (or other medications). The medications are essentially identical, but a pharmacy can fill the wrong one if the prescription is misread, which can cause insurance issues. Verify the box matches the prescription.
FAQ
What is the starting dose of Mounjaro? The starting dose is 2.5 mg once weekly for 4 weeks. This is an initiation dose, not a maintenance dose. After 4 weeks, the dose increases to 5 mg, which is the lowest maintenance dose.
How often do you increase Mounjaro dose? The minimum interval is 4 weeks at each dose. Most patients escalate every 4 weeks if tolerating well, or every 6 to 8 weeks if dealing with side effects. Some patients hold at a lower dose indefinitely if their A1C and weight goals are met.
What is the maximum dose of Mounjaro? The maximum approved dose is 15 mg once weekly. Most patients don't need 15 mg; the typical maintenance dose is 10 mg. Higher doses have slightly more side effects with diminishing additional A1C and weight benefit.
Can I skip from 2.5 mg to 10 mg? No. The label requires escalation in 2.5 mg increments (2.5 to 5 to 7.5 to 10, etc.). Skipping doses is associated with significantly higher discontinuation due to side effects. Each step requires at least 4 weeks at the prior dose.
How long should I stay on 5 mg Mounjaro? Minimum 4 weeks before considering escalation, no maximum. Many patients stay at 5 mg as their maintenance dose if A1C and weight outcomes are acceptable. Dose decisions should be made with the prescribing provider.
What if I miss a Mounjaro dose? If less than 4 days late, take it as soon as you remember and continue your regular schedule. If 4 or more days late, skip the missed dose and take your next dose on the regular schedule. Do not double up.
Can I take Mounjaro every other week instead of weekly? No, this is not the approved schedule. Tirzepatide has a half-life of about 5 days, so weekly dosing maintains stable levels. Every-other-week dosing produces inconsistent effects and is associated with worse outcomes.
How do I convert Mounjaro doses to compounded tirzepatide units? At the most common compounded concentration (10 mg/mL), 1 mg equals 10 units on a U-100 insulin syringe. So 5 mg = 50 units, 10 mg = 100 units. At other concentrations the math changes; check your vial label.
Is Mounjaro 5 mg the same as Zepbound 5 mg? Yes, they're identical. Same active ingredient (tirzepatide), same pen design, same dose strength. The labels differ because Mounjaro is FDA-approved for type 2 diabetes and Zepbound for weight management.
How much weight do you lose on each dose of Mounjaro? At 52 weeks: 5 mg averages -7.6 kg, 10 mg averages -10.7 kg, 15 mg averages -12.4 kg. Individual results vary substantially based on diet, exercise, and adherence.
Can I split Mounjaro pen doses? No. Mounjaro pens deliver a fixed dose. They are not designed to be split, and attempting to do so risks underdosing or device damage. Compounded tirzepatide vials allow dose flexibility but require physician guidance.
Should I escalate Mounjaro if I'm losing weight at a lower dose? Not necessarily. If you're hitting weight or A1C goals at 5 or 7.5 mg, staying at that dose is reasonable. Escalation makes sense when progress has stalled and you're tolerating the current dose well.
How long does it take Mounjaro to work? Most patients see appetite reduction within 1 to 2 weeks of the first dose. Measurable weight loss typically appears by week 4. A1C reduction is detectable by week 8 to 12 and continues improving for 6 to 12 months.
Can I take Mounjaro on different days of the week? You can choose any day of the week for your regular injection, but stick with that day consistently. Changing the day requires waiting at least 3 days between injections to maintain the weekly interval.
What time of day is best for Mounjaro? Time of day doesn't affect effectiveness because tirzepatide has a long half-life. Pick a time that's consistent and convenient. Some patients prefer evening injection so they sleep through any peak nausea after a dose.
Author / review note
Reviewed by the FormBlends Medical Team. References include the Mounjaro FDA prescribing information (rev. 2024), the SURPASS clinical trial program (Rosenstock et al., SURPASS-1, Lancet, 2021; Frias et al., SURPASS-2, NEJM, 2021), and Eli Lilly's published patient dosing guides 2024.
Related reading on FormBlends:
- /articles/glp1-hub/tirzepatide-dosing-units
- /articles/comparison/mounjaro-vs-zepbound/
- /articles/storage-and-travel/glp-1-travel-storage/
Sources
- The Mounjaro FDA prescribing information (rev. 2024).
- The SURPASS clinical trial program (Rosenstock et al., SURPASS-1, Lancet, 2021; Frias et al., SURPASS-2, NEJM, 2021).
- Eli Lilly's published patient dosing guides 2024.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. KwikPen is a trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →